skip to content

The Abell Group

 

Fragment-based approaches to enzyme inhibition

We are interested in applying fragment-based drug discovery to develop novel inhibitors. This involves the screening of a fragments library against a target using an array of biophysical techniques. Once the fragments have been identified, these are elaborated using synthetic and medicinal chemistry to develop high affinity inhibitors. We are interested in applying this methodology to a range of enzymes from Mycobacterium tuberculosis and drug resistant bacteria associated with Cystic Fibrosis. 

Read more on our work:

Microdroplets

We develop microfluidic microdroplet reactors for applications in biology and material sciences. Experiments are carried out in small water droplets, microdroplets, separated from each other by a continuous oil phase, within a microfluidic channel. We develop devices to generate and manipulate the droplets, and develop new analytical approaches to follow what is happening, on a very small scale, inside the droplets.